News

US Biosecure Act: Opportunities and Challenges for India’s Pharma Industry

For India, the Biosecure Act offers a chance to expand its already substantial role in the global pharmaceutical market. However, the legislation also introduces new pressures, demanding that Indian companies meet higher regulatory standards and improve manufacturing practices to fully capitalize on this opportunity.

• By Pooja Chaturvedi Sah
• New Delhi
• Sep 09, 2024

News

The U.S. is on the verge of passing the Biosecure Act, a landmark piece of legislation that could dramatically reshape the global biotechnology and pharmaceutical supply chains. While the Act is primarily aimed at reducing U.S. reliance on Chinese biotech companies, it carries significant implications for India, which is emerging as a critical alternative supplier of pharmaceutical products to the United States. 

For India, the Biosecure Act offers a chance to expand its already substantial role in the global pharmaceutical market. However, the legislation also introduces new pressures, demanding that Indian companies meet higher regulatory standards and improve manufacturing practices to fully capitalize on this opportunity. 

Understanding the Biosecure Act: Redefining U.S. Pharma Supply Chains 

The Biosecure Act is part of a broader U.S. strategy to secure its biotech and pharmaceutical supply chains, which have become increasingly reliant on China. The Act would bar U.S. federal agencies from contracting with or funding companies that use biotechnology equipment or services from certain Chinese firms deemed a national security threat. Companies like WuXi AppTec, BGI, and WuXi Biologics are among the "biotechnology companies of concern" targeted by the legislation. 

The scope of the Biosecure Act is wide-ranging, covering everything from genetic sequencing technologies to data storage systems related to biological materials. It reflects growing U.S. fears that China's dominance in biotechnology could be leveraged for espionage, bioterrorism, or geopolitical advantage. 

According to the U.S. Department of Commerce, China accounts for roughly 25% of global biotechnology sales, with a market size of $1.6 trillion in 2023. For comparison, India’s biotech sector, though expanding rapidly, was valued at $70 billion in 2022, with a compound annual growth rate (CAGR) of around 15%. 

U.S. Pharma: Pivoting Away from China 

The U.S. pharmaceutical sector, the largest in the world with a market value of $1.42 trillion, relies heavily on Chinese companies for drug development services, including Active Pharmaceutical Ingredients (APIs) and Contract Development and Manufacturing Organizations (CDMOs). 

As of 2023, China exported approximately $40 billion worth of APIs annually, accounting for nearly 40% of the global API market. Comparatively, India’s API exports stand at around $4 billion, underscoring China’s dominance. 

However, geopolitical tensions between the U.S. and China have prompted Washington to reconsider its dependence on Chinese pharma supply chains. In 2021, 13% of FDA-inspected Chinese pharmaceutical facilities were found non-compliant with U.S. manufacturing standards, raising concerns over the quality and reliability of imports from China. This has led to U.S. policymakers pushing for alternatives, and the Biosecure Act is a direct response. 

By limiting Chinese companies' access to federal contracts and funding, the Act effectively forces U.S. companies to seek alternative suppliers. India, with its lower manufacturing costs and well-established generics industry, is a natural fit for filling the gap. 

India’s Pharma Industry: A Rising Power, But With Hurdles 

India is already a major supplier of generic drugs to the U.S., accounting for around 40-50% of the U.S. supply of generics. Indian pharmaceutical exports to the U.S. are valued at $8.15 billion annually, making the U.S. the largest single market for Indian pharma products. 

India also houses the largest number of U.S. FDA-approved manufacturing facilities outside the U.S., with over 700 registered plants. Moreover, India’s CDMO industry is gaining global traction, though it currently holds only a 2.7% share of the global market, compared to China’s 8%. In 2024, India’s CDMO market is projected to grow to INR 18,800 crore (approximately $2.5 billion), driven by increasing demand from global pharmaceutical giants looking to diversify their supply chains. 

Despite these strengths, India’s pharmaceutical industry faces significant challenges. The World Health Organization (WHO) recently flagged several Indian drug manufacturers for quality control issues, after contaminated cough syrups produced in India were linked to deaths in The Gambia and Uzbekistan. These incidents have heightened scrutiny of Indian drug manufacturing practices, particularly from U.S. regulators. 

According to the U.S. Food and Drug Administration (FDA), 13% of Indian pharmaceutical facilities inspected in 2023 were issued "Official Action Indication" notices, signaling non-compliance with U.S. regulatory standards. Problems cited included inadequate quality control and data integrity issues in the production of generic drugs and APIs. 

Addressing these issues will be critical for India to maintain and expand its market share in the U.S. under the new Biosecure framework. 

U.S.-India Pharma Cooperation: What’s at Stake? 

If India can address its regulatory shortcomings, the Biosecure Act could significantly strengthen U.S.-India pharmaceutical cooperation. Indian CDMOs are already seeing increased interest from U.S. biotech firms, with partnerships expected to rise as U.S. companies pivot away from China. 

Indian drugmakers like Cipla, Sun Pharma, and Dr. Reddy’s Laboratories stand to gain, particularly in the contract manufacturing space. India’s pharmaceutical exports to the U.S. could see an uptick as a result of the Biosecure Act. Some analysts predict that India’s API exports could grow three- or four-fold in the next decade, fueled by U.S. demand for alternative sources. 

India’s generic drug industry is also expected to benefit, as U.S. pharmaceutical companies continue to rely on Indian suppliers for cost-effective alternatives to branded drugs. However, the Act also presents a competitive threat to India. The US administration has been pushing U.S. pharmaceutical companies to "reshore" drug manufacturing, investing heavily in domestic CDMO and API capabilities. The U.S. government allocated $60 million to the Biomedical Advanced Research and Development Authority (BARDA) in 2023 to boost domestic manufacturing capacity, a trend that is expected to continue. This could limit the long-term growth potential for Indian pharmaceutical exports to the U.S. 

Navigating the Future: India’s Path Forward 

For India to fully capitalize on the Biosecure Act, it will need to address several key areas: 

1. Regulatory Reforms: Working with the U.S. FDA standards will be critical for India’s pharma industry. India’s Drug Controller General has increased the frequency of inspections, and the U.S. FDA has announced more unannounced inspections of Indian facilities, signaling a push for greater transparency and accountability. Building stronger ties with U.S. regulators, such as through cooperative agreements, could ease some of the friction that has arisen due to quality control concerns. 

2. Reducing Dependence on China: Despite its potential as an alternative supplier, India remains heavily reliant on China for APIs and other critical raw materials. In FY 2023-24, 43.45% of India’s pharmaceutical imports, including APIs, came from China. To reduce this dependency, India has launched the Production-Linked Incentive (PLI) scheme, allocating INR 15,000 crore (about $2 billion) to boost domestic API manufacturing. However, uptake has been slow, and the Biosecure Act may be the catalyst needed to accelerate these efforts. 

3. Boosting CDMO Capabilities: With over 100 CDMOs and a rapidly growing market, India is well-positioned to capture more of the global CDMO market. The CDMO sector is expected to reach $44.63 billion by 2029, growing at a CAGR of almost 15%. This growth will depend on India’s ability to innovate and offer high-quality, reliable services to international clients. 

Conclusion: A Balanced Future for U.S.-India Pharma Relations 

The U.S. Biosecure Act is set to disrupt global pharma supply chains, with major implications for both India and the United States. For India, the Act offers an opportunity to expand its role as a supplier of pharmaceutical products to the U.S., potentially boosting exports and strengthening its CDMO and API industries. However, this opportunity comes with significant challenges, particularly in the areas of regulatory compliance and manufacturing quality. For the U.S., the Biosecure Act is a crucial step in reducing reliance on China, but it also highlights the importance of building strong, reliable partnerships with other countries, including India. 

As both nations navigate the evolving pharmaceutical landscape, a collaborative approach will be essential to ensuring that both sides can benefit from the opportunities—and mitigate the risks—presented by the recent legislation.